Sodium Iodide [124I]

This radiopharmaceutical is for diagnostic use only.
Sodium iodide [124I] injection may be given as a small tracer dose to study radioiodine pharmacokinetics. An estimation of the thyroid uptake and the effective elimination half-life in the thyroid prior to radioiodine therapy is used for the calculation of the required therapeutic activity of iodine-131 [1].

   
  • Packaging: 15 mL colourless type I glass single-dose vial.
  • Calibration: Thursday 12:00 p.m. CET, same week.
  • Availability: Dispensed every Monday. Only available for clinical trials or on patient name basis.

:

Fact Sheet: Sodium iodide [124I] injectionDownload



Product Specification
Name Sodium iodide [124I] injection
Pharmaceutical form Solution for injection
Activity concentration 37 MBq/mL at time and date of calibration
Radiochemical purity > 95.0%
Radionuclidic purity ≥ 99.5%
pH and composition 7.0 – 10.0 – Sodium chloride, sodium hydrogen phosphate, disodium hydrogen phosphate, sodium thiosulphate, sodium hydroxide, water for injection
Storage Store in the original packaging at controlled room temperature (< 25°C).
Expiry 96 hours from the time of calibration
Isotope Iodine-124


Iodide is the classic element for nuclear medicine and therapy, featuring some unique advantages. In the human body iodine is only stored in the thyroid, resulting in extreme target-to-background ratios. And that is exactly what is needed, both in diagnostics and therapy [1].

A sodium iodide injection can be given as a small tracer dose to study radioiodine pharmacokinetics. By estimating the thyroid uptake and the effective elimination half-life in this gland, specialists are able to calculate the required therapeutic activity of iodine-131 ([131I]).

Where to buy
Info request about Sodium iodide [124I] injection can be directly sent to web@cyclotron.nl.

Notes
(Click on the PMID to see abstracts from PubMed/NCBI)

[1] Bockisch A (2011). Matched pairs for radionuclide-based imaging and therapy. Eur J Nucl Med Mol Imaging 38 (Suppl 1): \S1–\S3. PMID: 21484377.

Further reading suggestions
(Click on the PMID to see abstracts from PubMed/NCBI)

   
  • Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2267-76. PMID: 20661558.

   
  • Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S48-56. PMID: 21484380.

   
  • Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radio-iodine therapy of differentiated thyroid cancer. J Nucl Med. 2008 Jun;49(6):1017-23. PMID: 18483099.

   
  • Kemerink GJ, Visser MG, Franssen R, Beijer E, Zamburlini M, Hal- ders SG, Brans B, Mottaghy FM, Teule GJ. Effect of the positron range of 18F, 68Ga and 124I on PET/ CT in lung-equivalent materials. Eur J Nucl Med Mol Imaging. 2011 May;38(5):940-8. PMID: 21287170.

   
  • Lopci E, Chiti A, Castellani MR, Pepe G, Antunovic L, Fanti S, Bombardieri E. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S28- 40. PMID: 21484381.

   
  • Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S10-8. PMID: 21484385.

   
  • Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (3D- RD) with 124I PET for 131I therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S41-7. PMID: 21484384.

   
  • Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E; European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1941-59. PMID: 18670773.






BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, BV Cyclotron VU produces GMP-compliant medical isotopes in state-of-the-art manufacturing facilities. They are used daily by pharmaceutical and biotechnological companies, medical device manufacturers, hospitals, clinics, and research laboratories.
Order our products directly from one of our distribution partners.